New Study Reveals Enhanced Antibiotic Effectiveness and Immune Synergy Against Drug-Resistant Bacteria

Research presented at IDWeek 2026 shows that cefiderocol’s effectiveness increases in physiologic conditions against key pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae. The drug also demonstrates strong synergy with the human antimicrobial peptide LL-37, particularly against resistant Acinetobacter baumannii. These findings suggest potential for improved treatment strategies in severe Gram-negative infections.

At IDWeek 2026, new data from Shionogi revealed that cefiderocol demonstrated a 76.7% clinical response rate in patients with carbapenem-resistant respiratory infections, particularly against difficult-to-treat Gram-negative pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae. In vitro testing further showed strong activity against ventilator-associated pneumonia (VAP) isolates of resistant P. aeruginosa. Notably, the drug’s effectiveness was enhanced under physiologic conditions, suggesting improved performance in real-world clinical settings. Additionally, cefiderocol exhibited significant synergy with the human antimicrobial peptide LL-37, especially against multidrug-resistant Acinetobacter baumannii, a pathogen known for limited treatment options. These findings were presented by Christine Slover, PharmD, Shionogi’s vice president of Infectious Diseases US Medical Affairs, who emphasized the clinical relevance of these results for providers managing severe infections.

The research builds on prior concerns about rising antibiotic resistance, particularly among carbapenem-resistant Gram-negative bacteria, which have prompted urgent calls for new therapeutic strategies. Cefiderocol, a siderophore cephalosporin, was previously developed to exploit bacterial iron-uptake systems, enabling it to penetrate resistant strains more effectively than older antibiotics. Shionogi’s presentation at IDWeek 2026 adds to growing evidence supporting cefiderocol’s role in the